Advice on the use of Leukomed Sorbact for preventing surgical site infection (SSI) to aid local decision making
Advice on the use of InterDry for intertrigo (inflammatory skin rash) to aid local decision making
Advice on the use of UroShield for preventing catheter-associated urinary tract infections (CAUTI) to aid local decision making
Advice on the use of SuperNO2VA for the relief of upper airway obstruction in people with obstructive sleep apnoea to aid local decision making
Advice on the use of the V.A.C. Veraflo Therapy system for infected wounds to aid local decision making
Advice on the use of Alpha-Stim AID for anxiety to aid local decision making
KTT22 Chemotherapy dose standardisation Key points Chemotherapy dose standardisation
KTT19 Psychotropic medicines in people with learning disabilities whose behaviour challenges Key points
KTT20 Safer insulin prescribing Key points Several new insulin products have been launched
KTT12 Type 2 diabetes mellitus: medicines optimisation priorities Key points The NICE
KTT18 Multimorbidity and polypharmacy Key points Multimorbidity is associated with
KTT5 Asthma: medicines safety priorities Key points Inhaled corticosteroids (ICS) are
KTT9 Antimicrobial stewardship: prescribing antibiotics Key points Antimicrobial resistance
KTT16 Anticoagulants, including direct-acting oral anticoagulants (DOACs) Key points
KTT3 Lipid-modifying drugs Key points The NICE guideline on cardiovascular disease:
KTT7 Antipsychotics in people living with dementia Key points The risks and limited
KTT14 Wound care products Key points A large number of wound dressings are available
KTT17 Acute kidney injury (AKI): use of medicines in people with or at increased risk of AKI Key points
KTT6 Hypnotics Key points The risks associated with hypnotics (including melatonin)
KTT21 Medicines optimisation in chronic pain Key points Controlling chronic pain can
KTT24 Suicide prevention: optimising medicines and reducing access to medicines as a means of suicide Key points
KTT23 Shared decision making Key points In the context of medicines optimisation, shared
Summary of the evidence on antimicrobial prescribing of meropenem with vaborbactam (Vaborem) to inform local NHS planning and decision making
Study will measure public’s preference for different health states
Chris Bird, Quality Standards Programme Manager, tells us how NICE developed the latest learning disability quality standards
As a public body, NICE is required to follow civil service principles on communicating during the lead up to the general election.
We estimate the costs or savings (budget impact) associated with technologies and guidelines so you can plan for and implement guidance.
NICE apps for android and apple devices. Includes BNF, BNFC and NICE guidance.
Our accreditation programme works with guidance producers seeking to renew their accreditation. We're keen to continue ongoing relationships with...
How the health and care system uses our recommendations to improve outcomes in priority areas.
Improving Access to Psychological Therapies (IAPT) services provide evidence-based psychological therapies to people with anxiety disorders and depression.
Our guidelines are based on the best available evidence. Our recommendations are put together by experts, people using services, carers and the public
We use 3 processes for assessing technologies: the single technology appraisal, the multiple technology appraisal and the fast track appraisal.
Contact the Office for Market Access (OMA)
Our licence allows individuals, commercial organisations and non-commercial organisations to reuse NICE content free of charge in their publications, products and systems.
Please complete all the required fields before submitting the form.RWE Navigator feedback form 1. Please tell us about yourself. Which
Terms and conditions for the National Institute for Health and Care Excellence
Book one of our scientific advice team to speak at your event
Find out more about why engaging with us early is important. We will: introduce NICE present NICE Scientific Advice explain how to complete the
Training seminars and workshops for those in the pharmaceutical, medical technology or cell and gene therapy sectors
Promoting independence through intermediate care - a quick guide for staff delivering intermediate care services.
Our associates help us to support and promote high quality, safe, cost-effective prescribing and medicines optimisation.
Designed for developers of medicinal products and other similarly regulated technologies. Receive advice from NICE, the European Medicines Agency...
Medtech guidance where there's no new research available that would effect the current guidance
Designed for those seeking advice in either pharmaceutical or medical technologies. Provides the highest level of detail of all our advice processes.
Designed for developers of medicinal products and other similarly regulated technologies. Allows you to seek joint regulatory advice from the...
Feedback from the GP reference panel survey
A timetable of quality standards topics for development has been agreed with the Department of Health and other key partners. Accredition decisions
NICE Medicines and technologies programme: adoption team
The National Institute for Health and Care Excellence (NICE) provides national guidance and advice to improve health and social care. Who we are